Užívání nivolumabu samotného nebo s kabozantinibem k prevenci návratu slizničního melanomu po operaci
Randomizovaná studie fáze II adjuvantního nivolumabu s nebo bez kabozantinibu u pacientů s resekovaným slizničním melanomem
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
- Slizniční melanom
- Anální melanom
- Melanom močového měchýře
- Cervikální melanom
- Melanom jícnu
- Melanom žlučníku
- Slizniční melanom ústní dutiny
- Slizniční melanom penisu
- Rektální melanom
- Recidivující slizniční melanom
- Sinonazální slizniční melanom
- Uretrální melanom
- Vaginální melanom
- Vulvární melanom
- Melanom sliznice hlavy a krku
- Melanom sliznice nosofaryngeálního sliznic
- Melanom sliznice močového systému
Intervence / Léčba
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVE:
I. To compare the efficacy of adjuvant nivolumab (480 mg every [q]4 weeks) versus nivolumab plus cabozantinib s-malate (cabozantinib) (40 mg daily) in patients with mucosal melanoma.
SECONDARY OBJECTIVES:
I. To compare overall survival between the two adjuvant therapies. II. To evaluate the adverse effects in each arm. III. To assess the correlation between PD-L1 expression in tumor cells with survival (recurrence free survival [RFS] and overall survival [OS]).
IV. To evaluate the overall response rate (ORR), duration of response (DOR), progression free survival (PFS), and OS of nivolumab plus cabozantinib in patients who cannot undergo gross total resection of disease or have metastatic disease at baseline.
V. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
OUTLINE: Patients whose tumor has been fully removed by surgery are randomized to Arm 1 or Arm 2. Patients whose tumor has not been fully removed by surgery or has spread are assigned to Arm 3.
ARM 1: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and cabozantinib orally (PO) once daily (QD) of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 3: Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo echocardiogram (ECHO) during screening and as clinically indicated throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.
After completion of study treatment, patients are followed up every 3 months until disease progression, and then every 6 months for up to 5 years from registration or until death.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- Ottawa Hospital and Cancer Center-General Campus
-
Toronto, Ontario, Kanada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Kanada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Jewish General Hospital
-
-
-
-
California
-
Auburn, California, Spojené státy, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Spojené státy, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Fremont, California, Spojené státy, 94538
- Palo Alto Medical Foundation-Fremont
-
Los Angeles, California, Spojené státy, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Spojené státy, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Spojené státy, 90033
- Los Angeles General Medical Center
-
Modesto, California, Spojené státy, 95355
- Memorial Medical Center
-
Newport Beach, California, Spojené státy, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Palo Alto, California, Spojené státy, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Spojené státy, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Spojené státy, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Spojené státy, 95816
- Sutter Medical Center Sacramento
-
San Francisco, California, Spojené státy, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Spojené státy, 94115
- California Pacific Medical Center-Pacific Campus
-
San Mateo, California, Spojené státy, 94401
- Mills Health Center
-
Santa Cruz, California, Spojené státy, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Spojené státy, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Spojené státy, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Spojené státy, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Englewood, Colorado, Spojené státy, 80113
- The Melanoma and Skin Cancer Institute
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Spojené státy, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Spojené státy, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Spojené státy, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Spojené státy, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Spojené státy, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Spojené státy, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Spojené státy, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Spojené státy, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Spojené státy, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Aurora, Illinois, Spojené státy, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Spojené státy, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University
-
Danville, Illinois, Spojené státy, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Spojené státy, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Spojené státy, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Spojené státy, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Spojené státy, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Spojené státy, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Spojené státy, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Spojené státy, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Spojené státy, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Lake Forest, Illinois, Spojené státy, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Spojené státy, 61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon, Illinois, Spojené státy, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Spojené státy, 60462
- Northwestern Medicine Orland Park
-
Springfield, Illinois, Spojené státy, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Spojené státy, 62702
- Springfield Clinic
-
Springfield, Illinois, Spojené státy, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Spojené státy, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Yorkville, Illinois, Spojené státy, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Spojené státy, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Spojené státy, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Spojené státy, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Spojené státy, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Spojené státy, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Spojené státy, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Spojené státy, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Spojené státy, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Spojené státy, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Battle Creek, Michigan, Spojené státy, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Spojené státy, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Spojené státy, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Spojené státy, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Spojené státy, 49009
- Beacon Kalamazoo Cancer Center
-
Muskegon, Michigan, Spojené státy, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Spojené státy, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Spojené státy, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Spojené státy, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Spojené státy, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Traverse City, Michigan, Spojené státy, 49684
- Munson Medical Center
-
Wyoming, Michigan, Spojené státy, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Burnsville, Minnesota, Spojené státy, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Spojené státy, 55433
- Mercy Hospital
-
Edina, Minnesota, Spojené státy, 55435
- Fairview Southdale Hospital
-
Minneapolis, Minnesota, Spojené státy, 55407
- Abbott-Northwestern Hospital
-
Robbinsdale, Minnesota, Spojené státy, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Spojené státy, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Spojené státy, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Spojené státy, 55102
- United Hospital
-
-
Missouri
-
Farmington, Missouri, Spojené státy, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Spojené státy, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Spojené státy, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Spojené státy, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Spojené státy, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Spojené státy, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Spojené státy, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Spojené státy, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Spojené státy, 59901
- Logan Health Medical Center
-
Missoula, Montana, Spojené státy, 59804
- Community Medical Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Spojené státy, 07920
- Memorial Sloan Kettering Basking Ridge
-
-
New York
-
Camillus, New York, Spojené státy, 13031
- Hematology Oncology Associates of CNY at Camillus
-
East Syracuse, New York, Spojené státy, 13057
- Hematology Oncology Associates of Central New York-East Syracuse
-
Harrison, New York, Spojené státy, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Spojené státy, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, Spojené státy, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Spojené státy, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Centerville, Ohio, Spojené státy, 45459
- Miami Valley Hospital South
-
Cincinnati, Ohio, Spojené státy, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Spojené státy, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Spojené státy, 44109
- MetroHealth Medical Center
-
Dayton, Ohio, Spojené státy, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Spojené státy, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Spojené státy, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Spojené státy, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Spojené státy, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Spojené státy, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Spojené státy, 45429
- Kettering Medical Center
-
Troy, Ohio, Spojené státy, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Lawton, Oklahoma, Spojené státy, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Spojené státy, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- UPMC Hillman Cancer Center
-
Willow Grove, Pennsylvania, Spojené státy, 19090
- Asplundh Cancer Pavilion
-
-
South Dakota
-
Rapid City, South Dakota, Spojené státy, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Avera Cancer Institute
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- UT MD Anderson Cancer Center
-
-
Virginia
-
Richmond, Virginia, Spojené státy, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Spojené státy, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Spojené státy, 54701
- HSHS Sacred Heart Hospital
-
Green Bay, Wisconsin, Spojené státy, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Spojené státy, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Madison, Wisconsin, Spojené státy, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Spojené státy, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Spojené státy, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Spojené státy, 54548
- Marshfield Medical Center - Minocqua
-
Oconto Falls, Wisconsin, Spojené státy, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake, Wisconsin, Spojené státy, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Spojené státy, 53081
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Stevens Point, Wisconsin, Spojené státy, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Sturgeon Bay, Wisconsin, Spojené státy, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Weston, Wisconsin, Spojené státy, 54476
- Marshfield Medical Center - Weston
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
STEP 0 INCLUSION CRITERIA
-
Histologically proven mucosal melanoma by local pathology
-
Central PD-L1 tumor tissue submission
-
STEP 1 INCLUSION CRITERIA
-
Receipt of the central PD-L1 testing results available
- Report is required for randomization of resection R0 or R1 patients
- Testing must be started in Step 0 but results can be reported after registration for resection R2 patients
-
Disease status-Resected R0 or R1 disease patients. Patients eligible for randomization have resected R0 or R1 disease (with negative margins or positive microscopic margins) that must meet one of the following 4 criteria as defined below:
-
Regional lymph node (LN) involvement; OR
-
In-transit metastases/satellite primary disease; OR
-
Single localized, primary disease meeting one of the following site-specific requirements:
-
Head/neck - Sinonasal (including nasopharynx): any primary lesion; Nasal or oral cavity; pT4a or above, given slightly improved OS
- NOTE: Conjunctival: does not meet the qualification for eligibility
-
Anorectal - any primary lesion
-
Vaginal/cervical - any primary, as they have 5 year OS rates of 5-25%
-
Urinary tract - any primary urethral or bladder tumor
-
Penile
-
Vulvar- American Joint Committee on Cancer (AJCC) cutaneous stage IIB or higher
-
Esophageal/gallbladder - any primary
-
-
Locoregionally recurrent following prior resection, meeting at least one of the above criteria
-
In addition, patients must have undergone cross-sectional imaging of the brain, chest, abdomen and pelvis with no evidence of distant metastatic disease
-
-
Disease status-Non-resected R2 or metastatic disease patients
- Non-resected R2 or metastatic disease that is assessable and measurable radiographically or by physical examination
-
Prior Treatment:
- No prior systemic checkpoint inhibitor therapy of mucosal melanoma, including in the adjuvant setting, is allowed. Prior adjuvant chemotherapy or interferon is allowed.
- No other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator. Exceptions may allow for adjuvant no evidence of disease (NED) cancers undergoing hormone based therapy may be eligible pending the other eligibility criteria are met and the principal investigator (PI) affirms the hormonal agent would not change the melanoma response.
- Any radiation must have completed 28 days prior to randomization and the patient must have adequately recovered from its effects.
- For resectable patients only: Surgery must have completed 28 days prior to randomization.
- For resectable patients only: Surgery must have completed no more than 84 days prior to randomization.
-
Not pregnant and not nursing, because this study has an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance (CrCl) >= 50mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Albumin >= 2.8 g/dL
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
-
No cardiovascular disease, including:
- No history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft (CABG) coronary angioplasty, or stenting within 6 months prior to study entry.
- No history of current class II or higher congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system.
- No refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg despite adequate attempts at anti-hypertensive therapy.
- No history of myocarditis.
- No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, history of Mobitz II second degree or third degree heart block without a permanent pacemaker in Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within the past 3 months.
- No corrected QT interval by Fridericia's formula (QTcF) > 500 msec. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard.
-
No underlying hematologic issues, including:
- Congenital bleeding diathesis
- Gastrointestinal (GI) bleeding requiring intervention within the past 6 months, unless directly related to mucosal melanoma
- Active hemoptysis within 42 days prior to study enrollment.
- Active tumor lesions with cavitations or tumor lesions which invade, encase, or abut major blood vessels. The anatomic location and characteristics of primary tumors or metastases as well as the medical history should be carefully reviewed in the selection of subjects for treatment with cabozantinib/placebo.
- Pulmonary emboli or deep vein thromboses (DVT) that require an active anticoagulation regimen.
- No known or suspected history of cytopenia (low white blood cell [WBC], hemoglobin or platelet count) of greater than 3 months duration with an unknown cause, myelodysplastic syndrome, or hematologic malignancies.
-
No clinical, laboratory or radiographic evidence of an active bacterial, fungal, or viral infection requiring treatment at the time of pre-registration (e.g., active symptoms of COVID-19 infection or a post-infectious symptomatic autoimmune syndrome, serious bacterial infections requiring antibiotics).
-
No known or suspected gastrointestinal disorder affecting absorption of oral medications.
-
Comorbid conditions:
-
No active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (> 10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
-
No history of autoimmune motor neuropathy (e.g., Guillain-Barre syndrome, myasthenia gravis) or non-infectious pneumonitis.
-
No history of severe allergic reactions to an unknown allergen or any components of the study drugs or its excipients.
-
No history of gastrointestinal perforation or abdominal fistula.
-
No clinically suspected central nervous system (CNS) (leptomeningeal or parenchymal) metastases. Patients with a history of CNS metastasis(s) will be allowed as long as
- The metastatic site(s) were adequately treated as demonstrated by clinical and radiographic improvement, AND
- The patient has recovered from the intervention (no residual adverse events > Common Terminology Criteria for Adverse Events [CTCAE] grade 1), AND
- The patient has remained without occurrence of new or worsening CNS symptoms for a period of 28 days prior to enrollment.
-
No history of seizure or any condition that may increase the patient's seizure risk (e.g., prior cortical stroke, significant brain trauma) within 2 years.
-
No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction.
-
No untreated spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression. Spinal metastases must have completed planned radiation or surgical therapy prior to registration.
-
-
Concomitant medications:
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 5 days prior to the start of study treatment.
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 5 days prior to the start of study treatment.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Arm 1 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Ostatní jména:
Undergo MRI
Ostatní jména:
Given PO
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo PET
Ostatní jména:
Given IV
Ostatní jména:
Undergo bone scan
Ostatní jména:
Undergo blood and tissue sample collection
Ostatní jména:
|
|
Aktivní komparátor: Arm 2 (nivolumab, placebo)
Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo PET
Ostatní jména:
Given IV
Ostatní jména:
Undergo bone scan
Ostatní jména:
Undergo blood and tissue sample collection
Ostatní jména:
Given PO |
|
Experimentální: Arm 3 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Ostatní jména:
Undergo MRI
Ostatní jména:
Given PO
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo PET
Ostatní jména:
Given IV
Ostatní jména:
Undergo bone scan
Ostatní jména:
Undergo blood and tissue sample collection
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Recurrence free survival (RFS)
Časové okno: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Will evaluate RFS of single agent adjuvant nivolumab plus placebo compared to the combination treatment of adjuvant nivolumab plus cabozantinib in patients with resected mucosal melanoma. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall survival (OS)
Časové okno: Number of days from registration until death (due to any cause, assessed up to 5 years
|
Will be evaluated utilizing the Kaplan-Meier (KM) method and, when appropriate, cox proportional hazards models. Median OS is calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model is built to compare arms 1 and 2 with respect to OS. |
Number of days from registration until death (due to any cause, assessed up to 5 years
|
|
RFS
Časové okno: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Median RFS will be calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model will also be built to compare arms 1 and 2 with respect to RFS, with and without stratifying for PD-L1 categorization. For non-resected cohort, If a patient in this group has surgery, their RFS data will be censored at the time of surgery. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
|
Progression free survival
Časové okno: Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
Will be evaluated in multiple settings utilizing the KM method and, when appropriate, cox proportional hazards models. |
Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
|
Objective response rate (Arm 3)
Časové okno: Up to 5 years
|
Will assess this endpoint utilizing a two-stage Simon that looks to improve from a rate of 20% to 47%. |
Up to 5 years
|
|
Duration of response (Arm 3)
Časové okno: Time from the first evidence of response until progression, assessed up to 5 years
|
A KM analysis is performed to calculate the median duration of response and 95% confidence intervals are constructed. |
Time from the first evidence of response until progression, assessed up to 5 years
|
|
Incidence of adverse events
Časové okno: Up to 5 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be summarized. |
Up to 5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Alexander N Shoushtari, Alliance for Clinical Trials in Oncology
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Techniky chemie, analytické
- Analýza spektra
- Nivolumab
- Manipulace se vzorkem
- Magnetická rezonanční spektroskopie
- Cabozantinib
Další identifikační čísla studie
Další identifikační čísla studie
- NCI-2021-11794
- U10CA180821 (Grant/smlouva NIH USA)
- NCI-2021-11794 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- A091903 (Jiný identifikátor: CTEP)
- A091903 (Jiný identifikátor: Alliance for Clinical Trials in Oncology)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .